Evidence map›Paper›PMID 41081050›Full record

ArticleFrontiers in cell and developmental biology2025

3D-ASC-Exos as a novel drug carrier for glioma treatment.

Xintong Han, Xin Li, Xinrui Yan, Yu Zhang, Chang Liu, Wei Liu, Rui Han, Yaxin Li, Jianming Li, Naichao Diao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xintong HanCollege of Agriculture, Yanbian University, Yanji, China.
Xin LiCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Xinrui YanCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Yu ZhangCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Chang LiuCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Wei LiuCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Rui HanCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Yaxin LiCollege of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Jianming LiJilin Province Sika Deer Efficient Breeding and Product Development Technology Engineering Research Center, Jilin Agricultural University, Changchun, China.
Naichao DiaoJilin Province Sika Deer Efficient Breeding and Product Development Technology Engineering Research Center, Jilin Agricultural University, Changchun, China.
Boyin JiaCollege of Agriculture, Yanbian University, Yanji, China.
Rui DuCollege of Agriculture, Yanbian University, Yanji, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: It is known that extracts from deer antler stem cells have an inhibitory effect on glioma growth. Therefore, it is hypothesized that exosomes derived from deer antler stem cells (ASC-Exos) can be used as a new drug carrier for the treatment of glioma. Methods: To begin with, we established a 3D culture system to obtain more exosomes and characterized the 3D-ASC-Exos. Subsequently, we loaded TMZ into 3D-ASC-Exos. Evaluate the effects of 3D-ASC-Exos loaded with TMZ on glioma cell proliferation, migration, invasion, and apoptosis at the cellular level. Additionally, the safety and efficacy of 3D-ASC-Exos loaded with TMZ against glioma were evaluated using tumor-bearing mice. Results: Compared with the 2D-ASC-Exos obtained from the traditional 2D culture, the 3D-ASC-Exos obtained from our constructed 3D culture system were concentrated nearly 30 times in the culture medium volume, which was more convenient for subsequent puriffcation. The two forms of ASC-Exos had similar morphologies and surface markers, but 3D-ASC-Exos were enriched with more miRNAs related to tumor suppression. In vitro experiments demonstrated that 3D-ASC-exosomes loaded with temozolomide (TMZ) inhibited the proliferation, migration and invasion abilities of glioma cells and promoted the apoptosis of glioma cells. The vivo tumor-bearing mouse model demonstrated that 3D-ASC-Exos loaded with TMZ exerted tumor-suppressive effects by inhibiting tumor growth and promoting tumor apoptosis. Meanwhile, the treatment with 3D-ASC-Exos loaded with TMZ caused no damage to the various tissues and organs of mice compared with the TMZ group. Discussion: 3D-ASC-Exos can be used as a novel drug carrier for glioma treatment. The development of 3D-ASC-Exos as a drug carrier not only provides a better strategy for tumor treatment, but also demonstrates the broad potential of exosomes in targeted tumor therapy.

Indexed as

3D-ASC-Exosantlerdrug carriergliomaTMZ

Identifiers

PMID41081050
PMCPMC12507771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.